Clinical Trial Protocol
Iranian Registry of Clinical Trials

23 Jun 2026

The effectiveness of memantin in the treatment of adult with attention deficit hyperactivity disorder

Protocol summary

Summary

The purpose is to study the efficacy of Memantin in the treatment of adult attention-deficit hyperactivity disorder (ADHD). Forty subjects between 18-45 years who clearly meet diagnostic criteria for adult ADHD, from parents and siblings of children with ADHD who are referred to child and adolescent psychiatric clinic of Sanandaj Behsat hospital will assign. Inclusion criteria: confirm of symptoms of ADHD in childhood & diagnosis of ADHD on clinical psychiatric interview. Exclusion criteria: any other psychiatric disorder and physical illness. This is a double blind randomized clinical trial study. Participants will be randomly allocated to receive Memantin (10 mg/day and will be titrated up to 20 mg/day after a week) and placebo for 6 weeks. Patients will assess at baseline, 3 and 6 weeks after the medication start with Adult Conner's questionnaires for assessing severity of symptoms of ADHD. Side effects will systematically record throughout the study and will assess using a checklist that comprises side effects by psychiatrist on weeks 1, 3 and 6.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2016053028182N1**
Registration date: **2017-01-10, 1395/10/21**
Registration timing: **registered_while_recruiting**

Last update:
Update count: **0**

Registration date

2017-01-10, 1395/10/21

Registrant information

Name

Soleiman Mohammadzadeh

Name of organization / entity

Kurdistan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 87 3323 2168

Email address

dr.mohammadzadeh86@muk.ac.ir

Recruitment status

Recruitment complete

Funding source

Kurdistan University of Medical Sciences

Expected recruitment start date

2016-03-19, 1394/12/29

Expected recruitment end date

2017-03-20, 1395/12/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effectiveness of memantin in the treatment of adult with attention deficit hyperactivity disorder

Public title

Use of memantin in treatment of adult with attention deficit hyperactivity disorder

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: receiving DSM-IV-TR diagnostic criteria for ADHD; the age range of 18 to 45 years old; not using any psychiatric drugs at least 2 weeks before the research. Exclusion criteria: having mental retardation; having any psychiatric disorders except Oppositional Defiant disorder; allergic history to Memantine; having serious disorder like heart disease; uncontrolled Seizure

disorder; individuals with Systolic blood pressure above 125 mmHg or resting pulse under 60 or having above 115 beats per minute: Pregnant and lactating women

Age
From **18 years** old to **45 years** old

Gender
Both

Phase
3

Groups that have been masked
No information

Sample size
Target sample size: **40**

Randomization (investigator's opinion)
Randomized

Randomization description

Blinding (investigator's opinion)
Double blinded

Blinding description

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee
Kurdistan University of Medical Sciences

Street address
Pasdaran Street, Kurdistan University of Medical Sciences

City
Sanandaj

Postal code

Approval date
2015-08-15, 1394/05/24

Ethics committee reference number
MUK.REC.1394.145

Health conditions studied

1

Description of health condition studied
Adult ADHD (Attention-deficit hyperactivity disorder)

ICD-10 code
F90.0

ICD-10 code description
Disturbance of activity and attention

Primary outcomes

1

Description
Improvement in hyperactivity symptome

Timepoint
Baseline, third and sixth weeks after intervention

Method of measurement
Conners' Adult ADHD Rating Scales–Self-Report

2

Description
Improvement in Impulsivity symptoms

Timepoint
Baseline, third and sixth weeks after intervention

Method of measurement
Conners' Adult ADHD Rating Scales–Self-Report

3

Description
Improvement in Attention-deficit symptoms

Timepoint
Baseline, third and sixth weeks after intervention

Method of measurement
Conners' Adult ADHD Rating Scales–Self-Report

Secondary outcomes

1

Description
drug side effects

Timepoint
third and sixth weeks after intervention

Method of measurement
checklist of side effects

2

Description
Efficacy in more than 50% of reduction in ADHD diagnostic rating scale

Timepoint
six weeks after treatment

Method of measurement
Parent interview

Intervention groups

1

Description
Therapeutic dosage of Memantine 10 mg is prescribed a tablet daily for the first week (one tablet in the night at 10;00 o'clock, and 2 tablets are daily prescribed in the second week (one tablet in the morning at 8;00 o'clock, one tablet at 10;00 o'clock).

Category
Treatment - Drugs

2

Description
Placebo is prescribed a tablet daily for the first week (one tablet in the night at 10;00 o'clock, and 2 tablets are daily prescribed in the second week (one tablet in the morning at 8;00 o'clock, one tablet at 10;00 o'clock).
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Behsat clinic, Behsat Hospital, Kurdistan University of Medical Sciences
Full name of responsible person
Soleiman Mohammadzadeh
Street address
Behsat Hospital, Vakil Street
City
Sanandaj

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Kurdistan University of Medical science
Full name of responsible person
Farzin Rezaei
Street address
Pasdaran Street, Kurdistan University of Medical Sciences
City
Sanandaj
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Kurdistan University of Medical science
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact
Name of organization / entity
Kurdistan University of Medical Sciences
Full name of responsible person
Soleiman Mohammadzadeh
Position
Child and Adolescent Psychiatry
Other areas of specialty/work
Street address
Behsat Hospital, Kurdistan University of Medical Sciences
City
Sanandaj
Postal code
Phone
+98 87 3328 5914
Fax
Email
dr.mohammadzadeh86@gmail.com
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Kurdistan University of Medical Sciences
Full name of responsible person
Soleiman Mohammadzadeh
Position
Child and Adolescent Psychiatry
Other areas of specialty/work
Street address
Behsat Hospital, Vakil Street
City
Sanandaj
Postal code
Phone
+98 87 3328 5914
Fax
Email
dr.mohammadzadeh86@gmail.com
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Kurdistan University Of Medical Science
Full name of responsible person
Soleiman Mohammadzadeh
Position
Child and Adolescent Psychiatrist, Assistant Professor
Other areas of specialty/work
Street address
Behsat Hospital, Vakil Street
City
Sanandaj
Postal code
Phone
+98 87 3328 5914
Fax
Email
dr.mohammadzadeh86@gmai.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty